雄激素剥夺作为早期疾病主要治疗方法的病例：来自J-CaP和CaPSURE的结果。
The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE.
作者信息
Akaza Hideyuki, Hinotsu Shiro, Usami Michiyuki, Ogawa Osamu, Kagawa Susumu, Kitamura Tadaichi, Tsukamoto Taiji, Naito Seiji, Hirao Yoshihiko, Murai Masaru, Yamanaka Hidetoshi, Namiki Mikio
机构信息
Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tennodai 1-1-1, Tsukuba, Ibaraki 305-8578, Japan.
出版信息
J Urol. 2006 Dec;176(6 Pt 2):S47-9. doi: 10.1016/j.juro.2006.06.070.
PURPOSE
We analyzed the outcome of primary androgen depletion therapy, which has gained more attention as a potential therapeutic option in patients with localized or locally advanced prostate cancer as it has been increasingly implemented despite limited data on its therapeutic impact in Japan and the United States.
MATERIALS AND METHODS
We analyzed data from CaPSURE and the Japanese Prostate Cancer study.
RESULTS
In Japan primary androgen depletion therapy has long been the treatment of choice for localized and locally advanced prostate cancer. Based on CaPSURE data the frequency of primary androgen depletion therapy being chosen to treat localized and locally advanced disease is also increasing in clinical practice in the United States. A study of the outcomes of endocrine therapy is currently being performed in Japan by the Japanese Prostate Cancer Study Group.
CONCLUSIONS
It is important to obtain such information about the role of primary androgen depletion therapy for localized and locally advanced prostate cancer from studies of natural history and clinical trials. It is also important to update practical treatment guidelines.
目的
我们分析了原发性雄激素剥夺疗法的结果，尽管在日本和美国关于其治疗效果的数据有限，但随着它在局限性或局部晚期前列腺癌患者中作为一种潜在治疗选择越来越多地被采用，该疗法已受到更多关注。
材料与方法
我们分析了来自CaPSURE和日本前列腺癌研究的数据。
结果
在日本，原发性雄激素剥夺疗法长期以来一直是局限性和局部晚期前列腺癌的首选治疗方法。根据CaPSURE数据，在美国临床实践中，选择原发性雄激素剥夺疗法治疗局限性和局部晚期疾病的频率也在增加。日本前列腺癌研究小组目前正在日本开展一项内分泌治疗结果的研究。
结论
从自然史研究和临床试验中获取有关原发性雄激素剥夺疗法在局限性和局部晚期前列腺癌中作用的此类信息非常重要。更新实用的治疗指南也很重要。
Zotero 插件